AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03058419
Drug: Omeprazole 20 mg
RxNorm normalized name: omeprazole 20 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive omeprazole 20 mg capsule (1\*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
Trial: NCT01138826
Drug: Amlodipine - reference
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet, single dose, with water
Trial: NCT01138826
Drug: Amlodipine ODT - test
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg orally disintegrating tablet (ODT), single dose, with water
Trial: NCT01138826
Drug: Amlodipine ODT - test
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg orally disintegrating tablet (ODT), single dose, without water
Trial: NCT03651466
Drug: Gx-G6
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.
Trial: NCT02566993
Drug: Lurbinectedin (PM01183)
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02566993
Drug: Vincristine (VCR)
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02566993
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03325465
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
Trial: NCT03325465
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
Trial: NCT03095118
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenously (IV) at a dose of 16 mg/kg once weekly for 8 weeks, followed by once every 2 weeks for eight additional doses
Trial: NCT00535587
Drug: pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02689245
Drug: Tenofovir
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02689245
Drug: Fecal Microbiota Transplantation (FMT)
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02902965
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
Trial: NCT00183885
Drug: mitomycin-c, cisplatin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
Trial: NCT02902965
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m\^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
Trial: NCT01621191
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT00148330
Drug: Triamcinolone acetate
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© \[40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia\]) was injected into the vitreous under sterile conditions in a minor procedures area.
Trial: NCT02998450
Drug: IMR-687
RxNorm normalized name: IMRCs
DrugBank: Human Embryonic Stem Cell-derived M Cell (DB15734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 of 6 possible single doses administered orally following overnight fast
Trial: NCT01457261
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
Trial: NCT00568815
Drug: Rituximab combined with ESHAP
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
Trial: NCT00232271
Drug: Clexane
RxNorm normalized name: Clexane
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03528785
Drug: Irinotecan Liposomal Injection [Onivyde]; oxaliplatin, 5-FU; Levofolinic Acid
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Oxaliplatin 60 mg/m2 IV in 120 minutes) on Days 1 and 15 of each cycle~* Irinotecan Liposomal Injection \[Onivyde\] (60 mg/m2 IV over 90 minutes) on Days 1 and 15 of each cycle~* Levofolinic acid (200 mg/m2 IV over 30 minutes) on Days 1 and 15 of each cycle~* 5FU (2.400 mg/m2 IV over 46 hours) on Days 1 and 15 of each cycle
Trial: NCT00995085
Drug: Extended Release Metadoxine
RxNorm normalized name: metadoxine
DrugBank: Metadoxine (DB16554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one oral 1400mg dose (2 tablets)
Trial: NCT04068974
Drug: Camrelizumab (SHR-1210)
RxNorm normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
Trial: NCT04068974
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.
Trial: NCT00976794
Drug: lithium plus carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability
Trial: NCT00976794
Drug: lithium plus valproate
RxNorm normalized name: valproate
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.~Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability.
Trial: NCT02957266
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly Cisplatin
Trial: NCT02957266
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly Gemcitabine
Trial: NCT02098421
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of oxytocin while the Foley bulb is in place
Trial: NCT02902965
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly~Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects \>75 years of age.~Following implementation of Protocol Amendment 4, dexamethasone administration was reduced to Days 1, 4, 8 and 11 during each 21-day cycle (Cycles 1-8) and on Days 1, 8, 22, 29 on each 42-day cycle (Cycles 9-12) and unchanged thereafter.
Trial: NCT01782508
Drug: imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: a selectively inhibits the KIT protein tyrosine
Trial: NCT01782508
Drug: Interferon
RxNorm normalized name: Interferon
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon belongs to the large class of glycoproteins known as cytokines.
Trial: NCT03083821
Drug: Baraclude
RxNorm normalized name: Baraclude
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified day
Trial: NCT02307643
Drug: MT-1303 Low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02307643
Drug: MT-1303 High dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01635062
Drug: Calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
Trial: NCT00166153
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03123861
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
Trial: NCT02980874
Drug: suprachoroidal CLS-TA
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprachoroidal injection of CLS-TA
Trial: NCT02980874
Drug: suprachoroidal sham
RxNorm normalized name: NIACINAMIDE 5 g in 100 g SUPRACHOROIDAL CREAM
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suprachoroidal sham procedure
Trial: NCT02980874
Drug: IVT aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 mg intravitreal injection of aflibercept
Trial: NCT00005965
Drug: bryostatin 1
RxNorm normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005965
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02206620
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04156620
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)
Trial: NCT00290394
Drug: rosiglitazone(drug), blood pressure lowering effect
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01346774
Drug: Cranberry powder capsules
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cranberry powder capsules twice a day
Trial: NCT02251691
Drug: Advagraf
RxNorm normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare the drug compliance between once daily or twice daily regimen
Trial: NCT02251691
Drug: Prograf
RxNorm normalized name: Prograf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compare the drug compliance between once daily or twice daily regimen
Trial: NCT02024373
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg (every evening orally) for 8 weeks
Trial: NCT01251458
Drug: Torisel
RxNorm normalized name: Torisel
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
Trial: NCT00389831
Drug: Rotigotine Nasal Spray
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
Trial: NCT00429520
Drug: Hyaluronic acid filler/IMD1 basic
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00369382
Drug: cyclosporine or tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
Trial: NCT00369382
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
Trial: NCT03487848
Drug: Daclatasvir
RxNorm normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days for specified duration
Trial: NCT03487848
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days for specified duration
Trial: NCT02170948
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
Trial: NCT01435226
Drug: GS-5885
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: GS-5885 tablet~GS-5885 tablet, 90 mg, QD
Trial: NCT01435226
Drug: GS-9451
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: GS-9451 tablet~GS-9451 tablet, 200 mg QD
Trial: NCT01435226
Drug: tegobuvir
RxNorm normalized name: Tegobuvir
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tegobuvir 30 mg BID
Trial: NCT01435226
Drug: placebo to match tegobuvir
DrugBank: Tegobuvir (DB11852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tegobuvir placebo BID
Trial: NCT01435226
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (Copegus®) BID (1000 mg for subjects weighing \< 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
Trial: NCT02394730
Drug: vorapaxar
RxNorm normalized name: Vorapaxar
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.5mg of vorapaxar taken orally once daily for 12 weeks
Trial: NCT01949948
Drug: Tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg single bolus intravenously
Trial: NCT01949948
Drug: Alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
Trial: NCT00134173
Drug: torcetrapib/atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00134173
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01506544
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg/kg of Hydroxyurea or the patient's standard daily dose
Trial: NCT02222324
Drug: E2609
RxNorm normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2609 will be administered as 8 tablets
Trial: NCT02222324
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as 1 tablet with 7 tablets of placebo matching E2609
Trial: NCT01946074
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered by intravenous infusion.
Trial: NCT01946074
Drug: ABBV-181
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-181 will be administered by intravenous infusion.
Trial: NCT00507546
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg nightly
Trial: NCT02452996
Drug: GNbAC1
RxNorm normalized name: Immunoglobulin G4, anti-(multiple sclerosis-associated retrovirus viral envelope protein) (human-mus musculus monoclonal gnbac1 heavy chain), disulfide with human-mus musculus monoclonal gnbac1 kappa-chain, dimer
DrugBank: Temelimab (DB15634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of IMP, IV infusion
Trial: NCT01136915
Drug: Iopamidol 370
RxNorm normalized name: iopamidol 370 mg iodine/mL (76 %) INTRAVEN KIT
DrugBank: Iopamidol (DB08947)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one time administration for PCI
Trial: NCT01121666
Drug: Follitropin alfa
RxNorm normalized name: Follitropin Alfa
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150IU per day subcutaneously for a maximum of 16 days
Trial: NCT04469621
Drug: SAR443122
RxNorm normalized name: SAR443122
DrugBank: SAR443122 (DB16492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule Route of administration: oral
Trial: NCT03896984
Drug: Radium-223 (Xofigo, BAY88-8223)
DrugBank: Radium Ra-223 (DB12813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ra-223 was approved by the FDA in May 2013 for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
Trial: NCT01136915
Drug: Iodixanol 320
RxNorm normalized name: IODIXANOL 320mgI/ml INJ
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodixanol 320 single injection for percutaneous coronary injection
Trial: NCT03896984
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone is a CYP17 inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2011, and for patients with metastatic high-risk castration-sensitive prostate cancer in 2018.
Trial: NCT03896984
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide is an androgen receptor inhibitor. It was approved by the FDA for the treatment of patients with mCRPC in 2012, with warning and precautions added in 2017 regarding the risk of seizure and encephalopathy.
Trial: NCT01144364
Drug: rituximab [Mabthera/Rituxan]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous repeating dose
Trial: NCT00375570
Drug: ME-609
RxNorm normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
DrugBank: Lactobacillus fermentum (DB16542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment 5 times daily for 5 days
Trial: NCT00102518
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
Trial: NCT03174951
Drug: IVIg
RxNorm normalized name: hIVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
Trial: NCT00856973
Drug: eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
Trial: NCT00856973
Drug: eszopiclone
RxNorm normalized name: Eszopiclone
DrugBank: Eszopiclone (DB00402)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
Trial: NCT00968760
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
Trial: NCT00968760
Drug: Carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/m\^2 IV over 1 hour on Day -6
Trial: NCT00968760
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2